194 related articles for article (PubMed ID: 36927002)
1. Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.
Sarfaty M; Golkaram M; Funt SA; Al-Ahmadie H; Kaplan S; Song F; Regazzi A; Makarov V; Kuo F; Ostrovnaya I; Seshan V; Zhao C; Greenbaum B; Liu L; Rosenberg JE; Chan TA
J Clin Oncol; 2023 Jun; 41(17):3225-3235. PubMed ID: 36927002
[TBL] [Abstract][Full Text] [Related]
2. Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.
Shao F; Jin K; Li B; Liu Z; Zeng H; Wang Y; Zhu Y; Xu L; Xu J; Wang Z; Chang Y; Zhang W
Urol Oncol; 2023 Oct; 41(10):433.e9-433.e18. PubMed ID: 37625906
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
[TBL] [Abstract][Full Text] [Related]
4. Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma.
Wang Y; Chen L; Ju L; Xiao Y; Wang X
Int Immunopharmacol; 2020 Oct; 87():106818. PubMed ID: 32738594
[TBL] [Abstract][Full Text] [Related]
5. A robust gene prognostic index composed of GZMB, IRF1, and TP63 can stratify the risk of two metastatic urothelial carcinoma cohorts based on immune checkpoint blockade therapy.
Lin J; Ding M; Qin C; Song Y; Yang W; Du Y; Xu T
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9877-9890. PubMed ID: 37247083
[TBL] [Abstract][Full Text] [Related]
6. CD8
Chen X; Xu R; He D; Zhang Y; Chen H; Zhu Y; Cheng Y; Liu R; Zhu R; Gong L; Xiao M; Wang Z; Deng L; Cao K
Oncogene; 2021 Oct; 40(43):6223-6234. PubMed ID: 34552192
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
Rose TL; Weir WH; Mayhew GM; Shibata Y; Eulitt P; Uronis JM; Zhou M; Nielsen M; Smith AB; Woods M; Hayward MC; Salazar AH; Milowsky MI; Wobker SE; McGinty K; Millburn MV; Eisner JR; Kim WY
Br J Cancer; 2021 Oct; 125(9):1251-1260. PubMed ID: 34294892
[TBL] [Abstract][Full Text] [Related]
8. Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile.
Peng M
Front Immunol; 2022; 13():970885. PubMed ID: 36003383
[TBL] [Abstract][Full Text] [Related]
9. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
Yan S; Zeng H; Jin K; Shao F; Liu Z; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Xu J
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35523436
[TBL] [Abstract][Full Text] [Related]
10. Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy
Fan B; Zheng X; Wang Y; Hu X
Pathol Oncol Res; 2023; 29():1611117. PubMed ID: 37082269
[No Abstract] [Full Text] [Related]
11. LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.
Shen R; Postow MA; Adamow M; Arora A; Hannum M; Maher C; Wong P; Curran MA; Hollmann TJ; Jia L; Al-Ahmadie H; Keegan N; Funt SA; Iyer G; Rosenberg JE; Bajorin DF; Chapman PB; Shoushtari AN; Betof AS; Momtaz P; Merghoub T; Wolchok JD; Panageas KS; Callahan MK
Sci Transl Med; 2021 Aug; 13(608):. PubMed ID: 34433638
[TBL] [Abstract][Full Text] [Related]
12. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
Voutsadakis IA
Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
[No Abstract] [Full Text] [Related]
13. The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer.
Boll LM; Perera-Bel J; Rodriguez-Vida A; Arpí O; Rovira A; Juanpere N; Vázquez Montes de Oca S; Hernández-Llodrà S; Lloreta J; Albà MM; Bellmunt J
Sci Rep; 2023 Sep; 13(1):15287. PubMed ID: 37714872
[TBL] [Abstract][Full Text] [Related]
14. Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature.
Aragaki AK; Jing Y; Hoffman-Censits J; Choi W; Hahn NM; Trock BJ; McConkey DJ; Johnson BA
Eur Urol Oncol; 2022 Jun; 5(3):338-346. PubMed ID: 34426176
[TBL] [Abstract][Full Text] [Related]
15. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250
[TBL] [Abstract][Full Text] [Related]
16. Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer.
Lin A; Qiu Z; Zhang J; Luo P
Front Immunol; 2021; 12():630773. PubMed ID: 33763074
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis.
Yoshida T; Ohe C; Ito K; Takada H; Saito R; Kita Y; Sano T; Tsuta K; Kinoshita H; Kitamura H; Nishiyama H; Kobayashi T;
Cancer Immunol Immunother; 2022 Nov; 71(11):2815-2828. PubMed ID: 35445305
[TBL] [Abstract][Full Text] [Related]
18. Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.
Wang L; Sfakianos JP; Beaumont KG; Akturk G; Horowitz A; Sebra RP; Farkas AM; Gnjatic S; Hake A; Izadmehr S; Wiklund P; Oh WK; Szabo PM; Wind-Rotolo M; Unsal-Kacmaz K; Yao X; Schadt E; Sharma P; Bhardwaj N; Zhu J; Galsky MD
Clin Cancer Res; 2021 Aug; 27(15):4287-4300. PubMed ID: 33837006
[TBL] [Abstract][Full Text] [Related]
19. Intragenic Rearrangement Burden Associates with Immune Cell Infiltration and Response to Immune Checkpoint Blockade in Cancer.
Zhang H; Lee S; Muthakana RR; Lu B; Boone DN; Lee D; Wang XS
Cancer Immunol Res; 2024 Mar; 12(3):287-295. PubMed ID: 38345376
[TBL] [Abstract][Full Text] [Related]
20. Novel biomarkers in bladder cancer.
Cheng ML; Iyer G
Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
